2.1
Olaparib (Lynparza, AstraZeneca) with abiraterone and prednisone or prednisolone is indicated for 'the treatment of adult patients with metastatic castration-resistant prostate cancer in whom chemotherapy is not clinically indicated'.
Olaparib (Lynparza, AstraZeneca) with abiraterone and prednisone or prednisolone is indicated for 'the treatment of adult patients with metastatic castration-resistant prostate cancer in whom chemotherapy is not clinically indicated'.
The dosage schedule is available in the summary of product characteristics for olaparib.
The list price for olaparib is £2,317.50 per pack of 56 tablets, each containing 100 mg or 150 mg of the active ingredient (excluding VAT; BNF online, accessed December 2023). The list price for abiraterone is £2,735 for a pack of 56 x 500 mg tablets (excluding VAT; BNF online, accessed December 2023).
The company has a commercial arrangement. This makes olaparib with abiraterone available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.